Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Dementia
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Heller, T.
Right arrow Articles by Heller, L.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

First among Equals?

Does drug treatment for dementia claim more than its fair share of resources?

Tom Heller

Open Universityt.d.heller{at}open.ac.uk

Lisa Heller

Longley Centre, Sheffieldlisah{at}chsheff-tr.trent.nhs.uk

Despite various problems associated with the introductionand use of the new generation of drugs for Alzheimer’s disease(cholinesterase inhibitors), expenditure on this aspect of patient care tends to eclipse expenditure on caring and support services. Even though evidence for the effectiveness of many patient-centred approaches is increasingly available, in the UK fixed budgets for various types of service usually means that increased expenditure on medication ensures that support services will inevitably have their funding eroded. Is this the best way to provide effective care for people with dementia? The role of drug companies in this process is examined critically.

Key Words: budgets • dementia • medication • pharmaceutical companies

Dementia, Vol. 2, No. 1, 7-19 (2003)
DOI: 10.1177/147130120300200102
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K Rockwood
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 677 - 685.
[Abstract] [Full Text] [PDF]